CD30+ Lymphoproliferative Disorders of the Skin

Hematol Oncol Clin North Am. 2017 Apr;31(2):317-334. doi: 10.1016/j.hoc.2016.11.006.

Abstract

Primary cutaneous CD30+ lymphoproliferative disorders encompass lymphomatoid papulosis (LyP), primary cutaneous anaplastic large cell lymphoma (pcALCL), and indeterminate cases. LyP is a benign disorder characterized by recurrent crops of red or violaceous papulonodules. Patients with LyP are at an increased risk of a secondary malignancy. pcALCL is characterized by a solitary red to violaceous nodule or tumor larger than 20 mm. LyP is benign, is limited to the skin, and self-resolves, with a 5-year survival rate of 100%; pcALCL is limited to the skin and responsive to directed therapies, with a 5-year survival rate of over 95%. Aggressive chemotherapeutic regimens should be avoided.

Keywords: CD30(+); Cutaneous lymphoproliferative disorders; Lymphomatoid papulosis; Primary cutaneous anaplastic large cell lymphoma; Secondary cutaneous anaplastic large cell lymphoma.

Publication types

  • Review

MeSH terms

  • Disease-Free Survival
  • Humans
  • Lymphoma, Large-Cell, Anaplastic / diagnosis
  • Lymphoma, Large-Cell, Anaplastic / drug therapy*
  • Lymphoma, Large-Cell, Anaplastic / metabolism
  • Lymphoma, Large-Cell, Anaplastic / mortality
  • Lymphomatoid Papulosis / diagnosis
  • Lymphomatoid Papulosis / drug therapy*
  • Lymphomatoid Papulosis / metabolism
  • Lymphomatoid Papulosis / mortality
  • Neoplasms, Second Primary / diagnosis
  • Neoplasms, Second Primary / drug therapy*
  • Neoplasms, Second Primary / metabolism
  • Neoplasms, Second Primary / mortality
  • Risk Factors
  • Skin Neoplasms / diagnosis
  • Skin Neoplasms / drug therapy*
  • Skin Neoplasms / metabolism
  • Skin Neoplasms / microbiology
  • Survival Rate